<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="971">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061474</url>
  </required_header>
  <id_info>
    <org_study_id>2016-3246</org_study_id>
    <nct_id>NCT03061474</nct_id>
  </id_info>
  <brief_title>Nicotinamide as an Early Alzheimer's Disease Treatment</brief_title>
  <acronym>NEAT</acronym>
  <official_title>A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test whether nicotinamide, also known as vitamin B3&#xD;
      or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that&#xD;
      accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild&#xD;
      Alzheimer's disease (AD) dementia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nicotinamide, the amide of nicotinic acid (vitamin B3/niacin), is an oral therapy with a&#xD;
      wealth of clinical data in a variety of therapeutic areas, including preliminary data&#xD;
      supporting its safety in Alzheimer's disease (AD). Preclinical work in a mouse model that&#xD;
      develops both plaques and tangles supports the hypothesis that nicotinamide can act as a&#xD;
      histone deacetylase (HDAC) inhibitor to reduce phosphorylation of tau.&#xD;
&#xD;
      The study will implement a group sequential design, incorporating a futility analysis with a&#xD;
      go/no-go decision conditional on cerebral spinal fluid CSF biomarker outcomes at 12-months.&#xD;
      The primary outcome for the trial is change in p-tau231.&#xD;
&#xD;
      This study timeline includes a screening phase of up to 60 days and treatment phase which is&#xD;
      expected to last about 48 weeks and will include 4 study visits.&#xD;
&#xD;
      An additional 12-month treatment and follow-up period is planned, contingent upon a &quot;go&quot;&#xD;
      decision based on the primary outcome (CSF p-tau231) or one planned secondary outcome (CSF&#xD;
      p-tau181)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind-Randomized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in p-tau 231</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in CSF phosphorylated tau (p-tau231) in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in p-tau 181</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in CSF phosphorylated tau (p-tau181) in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total tau</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in CSF total tau in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Nicotinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500mg twice daily: 2, 750mg tablets taken orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1500mg twice daily: 2, 750mg tablets taken orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide</intervention_name>
    <description>Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.</description>
    <arm_group_label>Nicotinamide</arm_group_label>
    <other_name>Niacinamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mild Cognitive Impairment (MCI) or dementia due to Alzheimer's disease (AD)&#xD;
&#xD;
          2. Biomarker criteria:&#xD;
&#xD;
             Cerebral Spinal Fluid (CSF) Amyloid Beta 1-42 (Aβ42) &lt;= 600 pg/mL, or A ratio of total&#xD;
             tau to Aβ42 ≥ 0.39.&#xD;
&#xD;
          3. Mini-Mental State Exam (MMSE) ≥ 20&#xD;
&#xD;
          4. Blood laboratories, urinalysis, and electrocardiogram are within normal limits or&#xD;
             deemed clinically not significant by the site investigator&#xD;
&#xD;
          5. Stable medications (including approved AD therapies) for at least 4 weeks&#xD;
&#xD;
          6. At least 6 years of education&#xD;
&#xD;
          7. Able to swallow oral tablets&#xD;
&#xD;
          8. Speaks English fluently&#xD;
&#xD;
          9. Available qualified study partner (≥3 times per week in-person communication with the&#xD;
             participant)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active neurological or psychiatric diagnosis other than AD that may affect cognition&#xD;
             and/or function. (Obstructive sleep apnea is permitted, if treated.)&#xD;
&#xD;
          2. Inability to undergo lumbar puncture, including use of Coumadin, novel oral&#xD;
             anticoagulants, clopidogrel, or dipyridamole. Use of aspirin &lt;= 325mg daily is&#xD;
             permitted.&#xD;
&#xD;
          3. Hachinski ischemic scale &gt; 4&#xD;
&#xD;
          4. Magnetic Resonance Imaging (MRI) incompatibility&#xD;
&#xD;
          5. MRI evidence of cortical stroke &gt;1cm, superficial siderosis, or extensive white matter&#xD;
             hyperintensity (Cardiovascular Health Study score 7-8+)&#xD;
&#xD;
          6. Diagnosis of cancer in the previous 5 years (with the exception of basal or squamous&#xD;
             cell carcinoma)&#xD;
&#xD;
          7. Geriatric Depression Scale (GDS) score &gt;6&#xD;
&#xD;
          8. History within the past 5 years of alcohol or substance use disorder&#xD;
&#xD;
          9. Laboratory evidence of a clinically significant abnormality that may interfere with&#xD;
             study assessments&#xD;
&#xD;
         10. Active partial or total malabsorptive disease (e.g., celiac disease)&#xD;
&#xD;
         11. Resides in a skilled nursing facility&#xD;
&#xD;
         12. Participation in a clinical trial of a potential disease-modifying therapy for AD in&#xD;
             previous 6-months (time between last investigational drug administration and baseline&#xD;
             for the current study)&#xD;
&#xD;
         13. Pregnant, lactating or of child bearing potential (that is, women must be 2 years&#xD;
             post-menopausal or surgically sterile to be considered not child bearing potential).&#xD;
&#xD;
         14. Unwillingness to abstain from over-the-counter nicotinamide for the duration of the&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Grill, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Psychiatry and Human Behavior</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008 Nov 5;28(45):11500-10. doi: 10.1523/JNEUROSCI.3203-08.2008.</citation>
    <PMID>18987186</PMID>
  </reference>
  <reference>
    <citation>Liu D, Pitta M, Jiang H, Lee JH, Zhang G, Chen X, Kawamoto EM, Mattson MP. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging. 2013 Jun;34(6):1564-80. doi: 10.1016/j.neurobiolaging.2012.11.020. Epub 2012 Dec 25. Erratum in: Neurobiol Aging. 2013 Sep;34(9):e3.</citation>
    <PMID>23273573</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Joshua Grill</investigator_full_name>
    <investigator_title>Associate Professor, Psychiatry &amp; Human Behavior</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Nicotinamide</keyword>
  <keyword>Niacinamide</keyword>
  <keyword>Niacin</keyword>
  <keyword>Nicotinic Acids</keyword>
  <keyword>Vitamin</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

